Attorney Docket No.: EX03-037C-US

Page 12 of 70 USSN: 10/533,555 Express Mail Tracking Number: EV 938 354 135 US

In the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claims 1-26 are pending in this Application.

Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, and 24 (currently amended) Claims 10, 11, 20, 21, 22, 23, 25, and 26 (cancelled)

Claims 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38 (new)

1. (currently amended) A compound represented by formula I,

$$X \longrightarrow \mathbb{R}^{5}$$

$$W \longrightarrow \mathbb{R}^{2}$$

$$I$$

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt, hydrate, or prodrug thereof, and wherein, each W is independently N or CR¹;

each R¹ is independently selected from -H, halogen, trihaloalkyl, -CN, -NH₂, -NO₂, -OR⁶, $-N=CNR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1,2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^7$, $-NC(O)R^6$, $-NCO_2R^6$, $-C(O)R^7$, $-R^7$, and -A-R⁷; provided at least one of R¹ is -A-R⁷, wherein, only for said at least one -A-R⁷, R⁷ must be an optionally substituted-heteroalicyclic ring, and any nitrogen of said optionally substituted heteroalicyclic ring cannot be directly bound to A, and where the heteroalicyclic ring of -A-R⁷ is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclylalkyl, heterocyclyl, alkoxy, Attorney Docket No.: EX03-037C-US Page 13 of 70 Express Mail Tracking Number: EV 938 354 135 US

USSN: 10/533,555

substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

A is O, $S(O)_{0-2}$, and NR^6 ;

L is O, $S(O)_{0-2}$, or NR^3 :

O is C or N, when O is N, then R⁴ does not exist;

R² and R³ are each independently -H or -R⁷;

R⁴ and R⁵ are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-NC(O)R^6$, $-NCO_2R^6$, $-C(O)R^7$, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

R⁶ is selected from -H, optionally substituted C₁₋₈alkyl, optionally substituted arylC₁₋₈alkyl, optionally substituted heterocyclylC₁₋₈alkyl, optionally substituted aryl, and optionally substituted heterocyclyl;

R⁷, for other than R⁷ in -A-R⁷, is selected from -H, optionally substituted C₁₋₈alkyl, optionally substituted arylC₁₋₈alkyl, optionally substituted heterocyclylC₁₋₈alkyl, optionally substituted aryl, and optionally substituted heterocyclyl; provided that there are at least two carbons between any heteroatom of R⁷ and A-or-either nitrogen to which R² [[or]] and R³ are attached; or

R⁶ and R⁷, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclic ring, said optionally substituted five- to seven-membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;

R⁸ is -H, -NO₂, -CN, -OR⁶, and optionally substituted C_{1.8}alkyl:

Page 14 of 70 Express Mail Tracking Number: EV 938 354 135 US

X is selected from one of the following six formulae:

wherein m is zero to five, n is zero to three, and Z is N or CR¹⁰;

 R^{10} is selected from -H, halogen, trihalomethyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and R⁷; K is O, S, or NR¹¹;

 R^{11} is selected from cyano, -NO₂, -OR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(O)R⁷, and R⁶; and

each R^{15} is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and R⁷.

- 2. (currently amended) The compound according to claim 1, wherein L is NR³; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- 3. (currently amended) The compound according to claim 2, wherein K is either O or NR¹¹; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- 4. (currently amended) The compound according to claim 3, wherein R² and R³ are each independently selected from -H and optionally substituted C₁₋₈alkyl, wherein

Attorney Docket No.: EX03-037C-US Page 15 of 70 Express Mail Tracking Number: EV 938 354 135 US

USSN: 10/533,555

substitution on the C₁₋₈alkyl of optionally substituted C₁₋₈alkyl is selected from NH₂, NO_2 , OR^6 , $N=CNR^6R^7$, NR^6R^7 , $N(R^6)C(=NR^8)NR^6R^7$, SR^6 , $S(O)_{1-2}R^6$, $SO_2NR^6R^7$. $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $N(R^6)SO_2R^6$, $-NC(O)R^6$, NCO₂R⁶, C(O)R⁷, heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

- The compound according to claim 4, wherein R² and R³ 5. (currently amended) are -H; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- 6. (currently amended) The compound according to claim 5, wherein only one of R^1 is -A- R^7 , where A is selected from O, $S(O)_{0-1}$, and NR^6 ; and for -A- R^7 , R^7 is an optionally substituted-heteroalicyclic ring optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclylalkyl, heterocyclyl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- The compound according to claim 6, wherein R⁶ is selected 7. (currently amended) from -H and C₁₋₈alkyl, said C₁₋₈alkyl optionally substituted with one or more groups each independently selected from NH2, NO2, OR6, N=CNR6R7, $NR^6R^7 - N(R^6)C(-NR^8)NR^6R^7 - SR^6 - S(O)_{1.2}R^6 - SO_2NR^6R^7 - CO_2R^6 - SO_2NR^6R^7 C(O)NR^6R^7 - C(O)N(OR^6)R^7 - C(-NR^8)NR^6R^7 - N(R^6)SO_2R^6 - NC(O)R^6 - NCO_2R^6 - NCO_2R^6$ C(O)R⁷, heterocyclic, alicyclic, and aryl; and R⁷ of -A-R⁷ is selected from the following optionally substituted heteroalicyclics: azetidine, perhydroazepinyl, piperidinyl, piperazinyl, azabicyclo[3.2.1]octyl, octahydro-cyclopenta[c]pyrroleyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolidinyl, dihydropyridinyl, tetrahydropyridinyl, quinuclidinyl,

Attorney Docket No.: EX03-037C-US

Page 16 of 70
USSN: 10/533,555

Express Mail Tracking Number: EV 938 354 135 US

tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl sulfone, and dioxaphospholanyl; where the heteroalicyclic is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclylalkyl, heterocyclyl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

8. (currently amended) The compound according to claim 7, wherein X is

m is 0 to 3, and R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and optionally substituted C₁₋₈alkyl; said C₁₋₈alkyl optionally substituted with one or more groups each independently selected from -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. (currently amended) The A compound according to claim 8, of formula II:

Attorney Docket No.: EX03-037C-US

Page 17 of 70
USSN: 10/533,555

Express Mail Tracking Number: EV 938 354 135 US

$$(R^{10})_{m} \xrightarrow{\parallel} \qquad \qquad N \qquad \qquad R^{5}$$

$$R^{7} \qquad \qquad N \qquad \qquad$$

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A, R⁴, R⁵, R¹⁰, and m are as defined above;

A is selected from O, S(O)₀₋₁, and NR⁶;

R⁷, in –A-R⁷, is selected from optionally substituted perhydroazepinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, and optionally substituted azetidine; wherein the ring nitrogen of R⁷ is substituted with a group R¹²; and R¹² is selected from a) -H, b) optionally substituted C₁₋₈alkyl, c) -SO₂R⁶, d) -SO₂NR⁶R⁷, e) -CO₂R⁶, f) -C(O)NR⁶R⁷, g) -C(O)R⁷, and h) an optionally substituted three- or four-carbon bridge between the ring nitrogen of R⁷ and a carbon vicinal to the ring nitrogen of R⁷; said three- or four-atom bridge optionally containing an oxygen in substitution for a carbon of the bridge; and where the C₁₋₈alkyl in b) and the bridge in h) are optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclylalkyl, heterocyclyl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

R⁶ is selected from -H and C₁₋₈alkyl;

 R^4 and R^5 are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

Attorney Docket No.: EX03-037C-US

Page 18 of 70
USSN: 10/533,555

Express Mail Tracking Number: EV 938 354 135 US

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and C₁₋₈alkyl; m is 0 to 3;

 R^7 , for other than R^7 in $A-R^7$, is selected from -H, C_{1-8} alkyl, aryl C_{1-8} alkyl, aryl, and heterocyclyl;

R⁸ is -H, -NO₂, -CN, -OR⁶, and C₁₋₈alkyl; and

each R^{15} is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷.

10. (canceled)

11. (canceled)

12. (currently amended) A The-compound according to claim 11, of formula III.

Ш

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R¹² is a C₁₋₄alkylene;

R¹³ is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and an heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R¹² which is directly attached to the ring nitrogen of the piperidine in formula III;

Attorney Docket No.: EX03-037C-US Page 19 of 70 Express Mail Tracking Number: EV 938 354 135 US

USSN: 10/533,555

R⁴ and R⁵ are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen. trihalomethyl, and -R⁷; or

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

R⁶ is selected from -H and C₁₋₈alkyl;

R⁷ is selected from -H, C₁₋₈alkyl, arylC₁₋₈alkyl, heterocyclylC₁₋₈alkyl, aryl, and heterocyclyl;

 R^8 is -H, -NO₂, -CN, -OR⁶, and C_{1-8} alkyl;

R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and $C_{1.8}$ alkyl; m is 0 to 3; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7 .

13. (currently amended) A The compound according to claim 12 formula IIIa,

IIIa

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein R¹² is a C₂₋₄alkylene; R¹³ is as defined above;

R¹³ is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group and an heteroalicyclic;

Attorney Docket No.: EX03-037C-US

Page 20 of 70

USSN: 10/533,555

Express Mail Tracking Number: EV 938 354 135 US

R¹⁰ is[[is]] selected from -H, halogen, perfluoroalkyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, NCO₂R⁶, -C(O)R⁷; R⁴ and R⁵ are each independently selected from -H, halogen, and C₁₋₄alkyl; or R⁴ and R⁵ combined are an optionally substituted phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclylalkyl, heterocyclyl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; and m is 0-3;

 R^6 is selected from -H and C_{1-8} alkyl, said C_{1-8} alkyl substituted with at least one of -CO₂H and -CO₂ C_{1-8} alkyl;

R⁷ is selected from -H, C₁₋₈alkyl, arylC₁₋₈alkyl, heterocyclylC₁₋₈alkyl, aryl, and heterocyclyl; and

 R^8 is -H, -NO₂, -CN, -OR⁶, and C₁₋₈alkyl.

- 14. (currently amended) The compound according to claim 13, wherein R¹² is an ethylene; R¹⁰ is halogen; R⁴ and R⁵ are each independently selected from -H, halogen, and C₁₋₂alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- 15. (currently amended) The compound according to claim 14, wherein each R¹⁰ is independently selected from fluorine and chlorine; R⁴ and R⁵ are each independently selected from -H and C₁₋₂alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.
- 16. (currently amended) The compound according to claim 15, wherein each R¹⁰ is independently selected from fluorine and chlorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

Attorney Docket No.: EX03-037C-US

Page 21 of 70
USSN: 10/533,555

Express Mail Tracking Number: EV 938 354 135 US

17. (currently amended) The compound according to claim 16, wherein R¹⁰ is fluorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

18. (currently amended) The compound according to claim[[1]] 17, selected from the following:

Entry	Name	Structure
1	(3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- yl](phenyl)methylidene]-5-{[1- (phenylmethyl)pyrrolidin-3-yl]amino}- 1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amine]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	
3	(3Z)-5-[(1-ethylpiperidin-4-yl)amine]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{[5-(methyloxy)-1H-benzimidazol- 2-yl][4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one	ZH ZH O
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](4-methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	ZH O
7	(3Z)-3-[1H-benzimidazol-2-yl(4- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	O ₂ N N N H O N H
8	(3Z)-3-{1H-benzimidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	
9	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
10	(3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- yl](phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	TZ AT O TZ O
11	(3Z)-3-[(4-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	H ₂ N N N N H
12	(3Z)-3-[1H-benzimidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	THE STATE OF THE S
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3- [[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	NO THE O

Entry	Name	Structure
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4- fluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F Z Z H
17	(3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
18	(3Z)-3-[1H-benzimidazol-2-yl(3- fluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
19	(3Z)-3-[1H-benzimidazol-2-yl(3- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	$\begin{array}{c c} O_2N & & N \\ \hline & & N \\ & & N \\ & & N \\ \end{array}$

Entry	Name	Structure
20	3-((Z)-1H-benzimidazol-2-yl{5-[(1- ethylpiperidin-4-yl)amino]-2-oxo-1,2- dihydro-3H-indol-3- ylidene}methyl)benzonitrile	NC NC NH O
21	(3Z)-3-[(3-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	H ₂ N N N N N N N N N N N N N N N N N N N
22	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-(piperidin- 4-ylamino)-1,3-dihydro-2H-indol-2- one	HN NH O
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1;2-dihydro-3H-indol-3-ylidene}methyl)benzenecarboximidamide	H ₂ N NH NH NH NH NH NH NH NH NH NH
24	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5 ({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
25	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	HN ZH O
26	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	N N N H N H N H N H N H N H N H N H N H
27	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI NH ON THE ON THE ONE OF THE ON
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	N N O N O N O N O N O N O N O N O N O N
29	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-({1-[2- (dimethylamino)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
30	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3- ylamino)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	NH N
32	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)oxy]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one	F N N H O N H
3 4	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (phenylmethyl)piperidin-4-yl]oxy}-1,3- dihydro-2H-indol-2-one	

Entry	Name	Structure
35	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one	CI ZET
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4-yl}oxy)- 1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
37	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4-yl}oxy)- 1,3-dihydro-2H-indol-2-one	CI ZH
38	(3Z)-3 [1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5 ((1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI ZH O
39	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI NHO NHO
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	
4 2	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-{2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	E HZ ZH O
43	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)(methyl)amino]- 1,3-dihydro-2H-indol-2-one	CI NH O
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one	CI NH ON THE ON

Entry	Name	Structure
45	(3Z)-3-[1H-benzimidazol-2-yl(4- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZII O
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4- fluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	E Z H
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZH O
49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one	F H Z Z H O Z H

Entry	Name	Structure
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	F N N H
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
52	(3Z)-3-[1H-benzimidazol-2-yl(4- fluoro-3-methylphenyl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI NH ON H
54	(3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N H O N H

Entry	Name	Structure
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2- yl)(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one	
59	(3Z)-5-{(1-ethylpiperidin-4-yl)amino}- 3-{1H-imidazol-2-yl(4- propylphenyl)methylidene}-1,3- dihydro-2H-indol-2-one	ZH O H

Entry	Name	Structure
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one	F ₃ C N N H
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	TZ ZH
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	ZH O
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-methyl-1H-imidazol-2-yl)(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F ₃ C N N N N N N N N N N N N N
· 66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZET O
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one	F N N N N N N N N N N N N N N N N N N N
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-1,3-dihydro-2H-indol- 2-one	F ₃ C N N N H
69	(3Z)-3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ZH O
71	(3Z)-3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 5-({1-[2-(methyloxy)ethyl]piperidin-4- yl]amino)-1,3-dihydro-2H-indol-2-one	F ₃ C N N N N N N N N N N N N N N N N N N N
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2- yl)(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI NH NH NH
73	(3Z)-3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F HZ ZH O
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
75	(3Z) 3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-((1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F ZH O ZH
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F Z Z H O Z H
79	(3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI ZH O
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-(piperidin-4- ylamino)-1,3-dihydro-2H-indol-2-one	F N N H O N H
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-piperidin- 1-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one	F HZ ZH O
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-morpholin- 4-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one	
84	(3Z)-5-({1-[2- (diethylamino)ethyl]piperidin-4- yl}amino)-3-[(3-fluorophenyl)(1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F HN N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-pyrrolidin- 1-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one	F ZHO
86	(3Z)-3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- methylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	NH N
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F N N H O N H
88	ethyl 2-{(Z)-(3-fluorophenyl)[5-({1-[2- (methyloxy)ethyl]piperidin-4- yl]amino)-2-oxo-1,2-dihydro-3H- indol-3-ylidene]methyl]-4-methyl-1H- imidazole-5-carboxylate	F N N O N H O N H
89	(3Z)-3-[1H-imidazol-2- yl(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
90	(3Z)-3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI ZHO
92	(3Z)-3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ₃ C F N N H O N H
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one	F H N N N N N N N N N N N N N N N N N N
94	(3Z)-3-[1H-imidazol-2-yl(4- propylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(4-phenyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F ZH O
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
98	(3Z)-3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ₃ C N N N N N N N N N N N N N N
99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(1H-1,2,4-triazol- 5-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F N N H O N H

Entry	Name	Structure
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F ₃ C P N N N N N N
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{(4-methyl-1H-imidazol-2-yl)[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one	F ₃ C N N N H
102	(3Z)-3-[(4-chlorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZHO
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F ₃ C F N N N H
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

Attorney Docket No.: EX03-037C-US USSN: 10/533,555

Entry	Name	Structure
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	CI HN NH O
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	E Z Z H O Z H
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(2-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one	F N H o and
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F ₃ C F N N H
109	(3Z)-3-[(2,3-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F Z H O Z H

USSN: 10/533,555

Entry	Name	Structure
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F Z Z H O Z H
112	(3Z)-3-[(2,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	HZ Z Z O HZ Z Z
113	(3Z)-3-[(2-fluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F ₃ C N H

Page 44 of 70 Express Mail Tracking Number: EV 938 354 135 US

Attorney Docket No.: EX03-037C-US

USSN: 10/533,555

Entry	Name	Structure
115	(3Z)-3-[(3-trifluoromethylphenyl)(-4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	F ₃ C N H O N H
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	CI Z ZH O ZH
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	CI NH NH O NH O
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	CI F N H N H O N H

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof

19. (currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1-18 claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Attorney Docket No.: EX03-037C-US Page 45 of 70 Express Mail Tracking Number: EV 938 354 135 US

USSN: 10/533,555

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound of claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; or comprising administering, to a mammal in need thereof, a therapeutically effective amount of the pharmaceutical composition as described in any one of claims 1-19 of claim 19.

25. (canceled)

26. (canceled)

- The method of Claim 24 where the disease or disorder is cancer. 27. (new)
- 28. (new) The method of Claim 27 where the cancer is non-small cell lung cancer, renal cell carcinoma, cancer of the large bowel, gastrointestinal cancer, ovarian cancer, acute myeloid leukemia, and multiple myeloma.
- The method of Claim 27 where the cancer is selected from squamous cell 29. (new) cancer, undifferentiated large cell cancer, adrenocarcinoma, and alveolar (bronchiolar) carcinoma.
- 30. (new) The method of Claim 24 where the disease or disorder is atherosclerosis.
- 31. (new) The compound of Claim 7 selected from

(3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- 10 yl](phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	HN NH N
---	--

25	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	HN HN HO
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3- ylamino)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	HZ HO THE
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one	F ₃ C N N N N N N N N N N N N N
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F ₃ C F N N N N N N N N N N N
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-1,3-dihydro-2H-indol- 2-one	F ₃ C N N N N H

USSN: 10/533,555

99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(1H-1,2,4-triazol- 5-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F N N N N N N N N N N N N N N N N N N N
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one	F ₃ C HN N N N N N
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{(4-methyl-1H-imidazol-2-yl)[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one	F ₃ C N N N N N N N N N N N N N
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F ₃ C F H N N H
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F ₃ C H N H O N H

Page 48 of 70 Express Mail Tracking Number: EV 938 354 135 US

Attorney Docket No.: EX03-037C-US

USSN: 10/533,555

114	(3Z)-3-[(3-trifluoromethylphenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F ₃ C N N H and
115	(3Z)-3-[(3-trifluoromethylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	F ₃ C N N N H

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

32. (new) The compound of Claim 9 selected from

1	(3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- yl](phenyl)methylidene]-5-{[1- (phenylmethyl)pyrrolidin-3-yl]amino}- 1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
30	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one	

32	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)oxy]-1,3- dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
34	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (phenylmethyl)piperidin-4-yl]oxy}-1,3- dihydro-2H-indol-2-one	
35	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one	ZH O ZH
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

Page 50 of 70 Express Mail Tracking Number: EV 938 354 135 US

Attorney Docket No.: EX03-037C-US

USSN: 10/533,555

37	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4-yl}oxy)- 1,3-dihydro-2H-indol-2-one	CI N N N N N N N N N N N N N N N N N N N
43	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)(methyl)amino]- 1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one	ST O
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-(piperidin-4- ylamino)-1,3-dihydro-2H-indol-2-one	HN NH and
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one	F HZ ZH O

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

Attorney Docket No.: EX03-037C-US USSN: 10/533,555

33. (new) The compound of Claim 12 selected from

6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](4-methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	HX N N N N N N N N N N N N N N N N N N N
12	(3Z)-3-[1H-benzimidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	HZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	HZ HO
22	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-(piperidin- 4-ylamino)-1,3-dihydro-2H-indol-2- one	HN N HN
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	H N O N O N O N O N O N O N O N O N O N

USSN: 10/533,555

50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	L ZII O
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F HZ ZH O
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2-yl(4- propylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	ZH ZH O
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N H O N H

64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-methyl-1H-imidazol-2-yl)(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one	HZ HO HZ HZ HO HZ
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one	F HN ZH O
69	(3Z)-3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	O N N N N N N N N N N N N N N N N N N N
86	(3Z)-3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- methylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	The state of the s

88	ethyl 2-{(Z)-(3-fluorophenyl)[5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-2-oxo-1,2-dihydro-3H- indol-3-ylidene]methyl}-4-methyl-1H- imidazole-5-carboxylate	F N N O O O O O O O O O O O O O O O O O
94	(3Z)-3-[1H-imidazol-2-yl(4- propylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	ZHO ZHO ZHO
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(4-phenyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one	F IN ZH O
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F HN NH and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N H O N N H

Attorney Docket No.: EX03-037C-US USSN: 10/533,555

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

34. (new) The compound of Claim 13 selected from

3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	H N N N N N N N N N N N N N N N N N N N
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{[5-(methyloxy)-1H-benzimidazol- 2-yl][4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one	H N N N N N N N N N N N N N N N N N N N
7	(3Z)-3-[1H-benzimidazol-2-yl(4- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	O ₂ N N N H
8	(3Z)-3-{1H-benzimidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	

	<u></u>	
9	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	H ₂ N ZH O
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3- [[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4- fluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

17	(3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	F Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
19	(3Z)-3-[1H-benzimidazol-2-yl(3- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	O_2N N N N N N N N N N
21	(3Z)-3-[(3-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	TZ ZH NGH NGH NGH NGH NGH NGH NGH NGH NGH NG
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1- ethylpiperidin-4-yl)amino]-2-oxo-1,2- dihydro-3H-indol-3- ylidene}methyl)benzenecarboximida mide	H ₂ N NH ₂ N N NH ₂ N N N N N N N N N N N N N N N N N N N

24	(3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
27	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI NH NH O
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI N N N N N N N N N N N N N N N N N N N
39	(3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	O H N N N N N N N N N N N N N N N N N N

45	(3Z)-3-[1H-benzimidazol-2-yl(4- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F HZ ZH O
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F Z ZH O
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2- yl)(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI N N N N N N N N N N N N N N N N N N N
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	F HN NH O

61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	N N N N N N N N N N N N N N N N N N N
89	(3Z)-3-[1H-imidazol-2- yl(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	N N H and
90	(3Z)-3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	DE LES CONTRACTOR OF THE PROPERTY OF THE PROPE

Attorney Docket No.: EX03-037C-US

USSN: 10/533,555

116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	CI ZH O
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	CI ZZH O ZH

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

35. (new) The compound of Claim 16 selected from

40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI N N N N N N N N N N N N N N N N N N N
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI N N N N N N N N N N N N N N N N N N N
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	E Z ZH O ZH
54	(3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F H N N N N N N N N N N N N N N N N N N
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZZH O
73	(3Z)-3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F X ZH O

74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
75	(3Z)-3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	E TZ ZI
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-({1- [2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N
79	(3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F N N N N N N N N N N N N N N N N N N N

80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	CI N N N H O N H
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	CI
102	(3Z)-3-[(4-chlorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	CI ZHO
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N N H O N H
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	CI N N N N N N N N N N N N N N N N N N N

109	(3Z)-3-[(2,3-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F Z ZH O
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	E Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F Z Z H O Z H
112	. (3Z)-3-[(2,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one	F N N H and
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one	CI F N N H O N H

Attorney Docket No.: EX03-037C-US USSN: 10/533,555

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

36. (new) A compound selected from

20	3-((Z)-1H-benzimidazol-2-yl{5-[(1- ethylpiperidin-4-yl)amino]-2-oxo-1,2- dihydro-3H-indol-3- ylidene}methyl)benzonitrile	NC NC N N N N N N N N N N N N N N N N N
71	(3Z)-3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 5-({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ₃ C ZH O
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4- triazol-5-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ₃ C F H N ZH
98	(3Z)-3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one	F ₃ C N N N N N N N N N N N N N N N N N N N

7-[(1 <i>H</i> -Benzoimidazol-2-yl)-(3-chloro-phenyl)-methylene]-2-[1-(2-methoxy-ethyl)-piperidin-4-ylamino]-5,7-dihydro-pyrrolo[3,2- <i>d</i>]pyrimidin-6-one	CI HN N N N N N N N N N N N N N N N N N N
E- and Z- of 3-[(1 <i>H</i> -Benzoimidazol-2-yl)-(3-chlorophenyl)-methylene]-5-[1-(2-methoxy-ethyl)-piperidin-4-yloxy]-1,3-dihydro-pyrrolo[3,2- <i>b</i>]pyridin-2-one	O ZH ZH O ZH

37. (new) The compound of Claim 18 selected from

(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

38. (new) The compound of Claim 18 selected from

(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.